|
Real-time Estimate
Cboe BZX
10:08:05 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 2.255 USD | -4.45% |
|
-7.73% | +26.11% |
| 08-12 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 190.1 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 31.36% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 190.1 | 190.1 | 190.1 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 31.36% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 12.4x | 19.7x | 118x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.5x | -1.4x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.38x | 2.79x | 2.76x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.38x | 2.79x | 2.76x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 10.4x | 22.4x | 168x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.19 | 0.12 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 79.8 | 68.19 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 18.35 | 8.476 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.38 | 10.01 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.360 | 2.360 | 2.360 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 3/31/22 | 2/27/23 | 3/14/24 | 3/17/25 | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.42x | - | - | - | 190M | |
| 34.32x | 12.47x | 25.45x | 0.57% | 1,078B | |
| 29.15x | - | - | 2.05% | 632B | |
| 32.02x | 7.45x | 15.48x | 2.73% | 443B | |
| 20.19x | 4.79x | 11.87x | 2.76% | 356B | |
| 21.62x | 5.6x | 13.97x | 2.87% | 289B | |
| 20.24x | 4.18x | 11.87x | 2.1% | 245B | |
| 26.43x | 6.88x | 12.21x | 2.41% | 226B | |
| 13.48x | 4.84x | 10.07x | 3.78% | 204B | |
| -42.9x | 6.13x | 34.58x | 2.39% | 171B | |
| Average | 16.70x | 6.54x | 16.94x | 2.41% | 364.39B | |
| Weighted average by Cap. | 24.53x | 8.19x | 18.66x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
